Pharma Mar (PHM) Corporate presentation summary

Strategic vision and leadership in marine oncology

• Focused on developing and commercializing anticancer drugs derived from marine sources, aiming to remain a global leader in marine medicinal innovation.

• Mission centers on improving cancer patient outcomes through novel therapies inspired by the sea.

Product portfolio and pipeline

• Three approved oncology products: Yondelis (trabectedin), Aplidin (plitidepsin), and Zepzelca (lurbinectedin), with established European sales force.

• Diversified pipeline includes late- and early-stage assets, with ongoing development in solid tumors and soft tissue sarcomas.

• Lurbinectedin is positioned as standard of care in 2nd line SCLC in the US and emerging in 1st line maintenance.

Clinical development and trial results

• IMforte Phase 3 trial showed statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) for lurbinectedin plus atezolizumab in extensive-stage SCLC.

• Safety profile of lurbinectedin plus atezolizumab was manageable, with most adverse events not leading to discontinuation.

• LAGOON Phase 3 trial in relapsed SCLC completed recruitment, with topline data expected in 2026.